Oral converting enzyme inhibitor in malignant hypertension.
- 1 March 1982
- journal article
- research article
- Published by BMJ in Archives of Disease in Childhood
- Vol. 57 (3), 235-237
- https://doi.org/10.1136/adc.57.3.235
Abstract
Malignant hypertension, which developed in a 9-yr-old boy after an episode of hemolytic uremic syndrome, could not be controlled with antihypertensive agents. Treatment with oral converting enzyme inhibitor (captopril) was effective in controlling the blood pressure and averted bilateral nephrectomy. No adverse effects from the drug were noted.This publication has 7 references indexed in Scilit:
- Increased Glomerular Filtration Rate after Converting-Enzyme Inhibition in Essential HypertensionNew England Journal of Medicine, 1979
- Oral Angiotensin-Converting Enzyme Inhibitor in Long-Term Treatment of Hypertensive PatientsAnnals of Internal Medicine, 1979
- Negative saralasin response in correctable renovascular hypertensionThe Journal of Pediatrics, 1978
- Antihypertensive Effect of the Oral Angiotensin Converting-Enzyme Inhibitor SQ 14225 in ManNew England Journal of Medicine, 1978
- Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive AgentsScience, 1977
- A SPECIFIC ORALLY ACTIVE INHIBITOR OF ANGIOTENSIN-CONVERTING ENZYME IN MANThe Lancet, 1977
- Minoxidil — An Alternative to Nephrectomy for Refractory HypertensionNew England Journal of Medicine, 1973